NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
MYRBETRIQ (mirabegron) by Ascentage Pharma is adrenergic beta3-agonists [moa]. Approved for overactive bladder, urgency incontinence, urge incontinence. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYRBETRIQ (mirabegron) is an oral extended-release tablet approved in 2012 that functions as a beta-3 adrenergic agonist. It represents a novel mechanism of action distinct from anticholinergics in the overactive bladder market. The product works by stimulating beta-3 adrenergic receptors in the bladder detrusor muscle to increase storage capacity. It is positioned as an alternative treatment option for patients who cannot tolerate or have contraindications to anticholinergic agents.
$2.5BPart D
3.9 years to LOEMechanism of Action
Adrenergic beta3-Agonists
Pharmacologic Class:
beta3-Adrenergic Agonist
Indications (3)
Worked on MYRBETRIQ at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.